Daily roundup of research and analysis from The Globe and Mail’s market strategist Scott Barlow BofA Securities analyst Travis Steed believes medical technology stocks are on sale, “Medtech sold off post Q1 as investors realized Q1 rev beats had catchup/easy Jan comps, year-over-year growth is decelerating and rev beats will get smaller (and some flows into Tech sector). Over the last month medtech is down 6 per cent … The short-term focus on owning medtech during the transition back to more sustainable year-over-year growth has created an attractive opportunity, in our view. Medtech is at a 9.5-per-cent premium to the...